Effect of Polygonatum odoratum extract on human breast cancer MDA-MB-231 cell proliferation and apoptosis

Tai,Yu; Sun,Yi‑Ming; Zou,Xue; Pan,Qiong; Lan,Ya‑Dong; Huo,Qiang; Zhu,Jing‑Wen; Guo,Fei; Zheng,Chang‑Quan; Wu,Cheng‑Zhu; Liu,Hao

doi:10.3892/etm.2016.3630

Effect of Polygonatum odoratum extract on human breast cancer MDA-MB-231 cell proliferation and apoptosis

Authors:
- Yu Tai
- Yi‑Ming Sun
- Xue Zou
- Qiong Pan
- Ya‑Dong Lan
- Qiang Huo
- Jing‑Wen Zhu
- Fei Guo
- Chang‑Quan Zheng
- Cheng‑Zhu Wu
- Hao Liu
View Affiliations

Affiliations: Department of Pharmacy, Bengbu Medical College, Bengbu, Anhui 233030, P.R. China, Department of Surgical Oncology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui 233004, P.R. China
Published online on: August 30, 2016 https://doi.org/10.3892/etm.2016.3630
Pages: 2681-2687

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Traditional Chinese medicine (TCM) is important in the provision of anti-tumor drugs. Recently, studies have shown that certain types of TCM agents are able to control the growth of tumors, enhance the body's immune function and enhance the therapeutic effect of chemotherapeutic drugs. In women, breast carcinoma is the most common tumor type and the second most common cause of death from cancer. Polygonatum odoratum (P. odoratum) is commonly used in TCM. The aim of the present study was to investigate the effects of P. odoratum extract on the proliferation and apoptosis of MDA‑MB‑231 breast cancer cells. Cell proliferation was assessed using MTT and colony formation assays. In addition, propidium iodide (PI)/Annexin V‑FITC staining was used to investigate the apoptosis of MDA‑MB‑231 cells following treatment with P. odoratum extract. The protein expression levels of B‑cell lymphoma‑2 (Bcl‑2) and Bcl‑2‑associated X protein (Bax) were also detected using western blot analysis, while a JC‑1 staining assay was used to assess the mitochondrial membrane potential (ΔΨm). The results of the MTT assay showed that the proliferation and colony formation of MDA‑MB‑231 cells were inhibited following treatment with the extract. Furthermore, the PI/Annexin‑V staining showed that the apoptosis of MDA‑MB‑231 cells was enhanced by the extract, in a concentration‑dependent manner. The extract also lowered the ΔΨm of MDA‑MB‑231 cells, upregulated the expression of Bax and inhibited the expression of Bcl‑2. In conclusion, these results showed that the P. odoratum extract inhibited the proliferation and induced apoptosis of breast cancer MDA-MB-231 cells.

View Figures

View References

1	Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
2	Kim SH, Son BH, Hwang SY, Han W, Yang JH, Lee S and Yun YH: Fatigue and depression in disease-free breast cancer survivors: prevalence, correlates, and association with quality of life. J Pain Symptom Manage. 35:644–655. 2008. View Article : Google Scholar : PubMed/NCBI
3	Fann JR, Thomas-Rich AM, Katon WJ, Cowley D, Pepping M, McGregor BA and Gralow J: Major depression after breast cancer: A review of epidemiology and treatment. Gen Hosp Paychiatry. 30:122–126. 2008.
4	Karakoyun-Celik O, Gorken I, Sahin S, Orcin E, Alanyali H and Kinay M: Depression and anxiety levels in woman under follow-up for breast cancer: Relationship to coping with cancer and quality of life. Med Oncol. 27:108–113. 2010. View Article : Google Scholar : PubMed/NCBI
5	Xu LX, Shen SS, He JJ, Fu Y, Xue XD, Liang Y, Lin Y, Zhang XH and He JC: Relationship among anxiety, depression, well-being index and social support in breast cancer patients. Zhong Guo Xin Li Wei Sheng Za Zhi. 27:473–478. 2013.
6	DeSantis C, Ma J, Bryan L and Jemal A: Breast cancer statistics, 2013. CA Cancer J Clin. 64:52–62. 2014. View Article : Google Scholar : PubMed/NCBI
7	Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mather C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015. View Article : Google Scholar : PubMed/NCBI
8	Green J, Cairns BJ, Casabonne D, Wright FL, Reeves G and Beral V: Million Women Study collaborators: Height and cancer incidence in the Million Women Study: prospective cohort, and meta-analysis of prospective studies of height and total cancer risk. Lancet Oncol. 12:785–794. 2011. View Article : Google Scholar : PubMed/NCBI
9	Mellemkjaer L, Christensen J, Frederiksen K, Baker JL, Olsen A, Sørensen TI and Tjønneland A: Leg length, sitting height and postmenopausal breast cancer risk. Br J Cancer. 107:165–168. 2012. View Article : Google Scholar : PubMed/NCBI
10	Ritte R, Lukanova A, Tjonneland A, Olsen A, Overvad K, Mesrine S, Fagherazzi G, Dossus L, Teucher B, Steindorf K, et al: Height, age at menarche and risk of hormone receptor-positive and -negative breast cancer: A cohort study. Int J Cancer. 132:2619–2629. 2013. View Article : Google Scholar : PubMed/NCBI
11	Kabat GC, Kim MY, Hollenbeck AR and Rohan TE: Attained height, sex, and risk of cancer at different anatomic sites in the NIH-AARP Diet and Health Study. Cancer Causes Control. 25:1697–1706. 2014. View Article : Google Scholar : PubMed/NCBI
12	Ni ZJ, Wang HS and Chen YX: The trend analysis of mortality with female breast cancer during 1989-2008, Haimen city. Jiang Su Yu Fang Yi Xue. 20:1–3. 2009.(In Chinese).
13	Pan XD, Wang HW and Li X: Breast cancer mortality tendency among women from 1992 to 2006 in Shenyang. Zhong Guo Fu You Bao Jian. 23:4703–4705. 2008.(In Chinese).
14	Wang Y, Ma Q, Li HQ, Diao YT, Yin C, Ciu YC, Xu AQ, Ma JQ and Guo XL: Changing trend of female breast cancer mortality in Shandong province, 1970-2005. Zhong Hua Zhong Liu Fang Zhi Za Zhi She. 16:729–732. 2009.(In Chinese).
15	Liang YQ: Analysis of female breast cancer mortality in Nanjing in 1997-2005. Zhi Ye Yu Jian Kang. 23:357–358. 2007.(In Chinese).
16	Blichert-Toft M, Nielsen M, During M, Møller S, Rank F, Overgaard M and Mouridsen HT: Long-term results of breast conserving surgery vs. mastectomy for early stage invasive breast cancer: 20-year follow-up of the Danish randomized DBCG-82TM protocol. Acta Oncol. 47:672–681. 2008.
17	Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thürlimann B and Senn HJ: 10th St. Gallen conference: Progress and promise: Highlights of the international expert consensus on the primary therapy of early breast cancer 2007. In: Ann Oncol. 18. pp. 1133–1144. 2007; View Article : Google Scholar : PubMed/NCBI
18	Ahunbay EE, Robbins J, Christian R, Godley A, White J and Li XA: Interfractional target variations for partial breast irradiation. Int J Radiat Oncol Biol Phys. 82:1594–1604. 2012. View Article : Google Scholar : PubMed/NCBI
19	Yamashiro H and Toi M: Molecular targeted therapy for breast cancer treatment, challenge to cure. Nihon Rinsho. 68:1854–1858. 2010.(In Japanese). PubMed/NCBI
20	Chen SS and Yu ZH: Recent research on traditional Chinese medicine in the treatment of breast cancer. Modern Oncology. 23:2072–2077. 2015.
21	Kim J, Han JY, Shaw B, McTavish F and Gustafson D: The roles of social support and coping strategies in predicting breast cancer patients' emotional well-being: Testing mediation and moderation models. J Health Psychol. 15:543–552. 2010. View Article : Google Scholar : PubMed/NCBI
22	Li J, Huang XY, Zou XZ, Wei W and Wang ZX: Clinical curative effect of traditional Chinese medicine, western medicine Fuzheng attack comprehensive treatment of malignant tumor. Zhong Guo Yi Yao Dao Kan. 3:529–530. 2014.(In Chinese).
23	Chen YE, Wang SP, Hu YY, Chen MW and Wang YT: Research in novel drug delivery system of anti-tumor Chinese medicine (part three) - Fuzheng guben Chinese medicine. Shi Jie Ke Xue Ji Shu-Zhong Yi Yao Xian Dai Hua. 2:201–206. 2013.(In Chinese).
24	Commission of Pharmacopoeia, . Chinese Pharmacopoeia: Part One. China Medical Science and Technology Press; Beijing: 2010
25	He Zhijun: A summary on 42 cases of type 2 diabetes treated by Gegeng Danshen Yuzhu decoction. Hu Nan Zhong Yi Za Zhi. 24:10–11. 2008.
26	Shu XS, Lv JH, Tao J, Li GM, Li HD and Ma N: Antihyperglycemice effects of total flavonoids from Polygonatum odoratum in STZ and alloxan-induced diabetic rats. J Ethnopharmacol. 124:539–543. 2009. View Article : Google Scholar : PubMed/NCBI
27	Yang HJ, Yang SH, Zhang HT, Ma L and Zhang LC: Polygonatum odoratum chemical composition, pharmacological effects research progress and the present situation of the development and utilization. Ren Shen Yan Jiu. 3:40–45. 2012.(In Chinese).
28	Li CY, Pan XY, Zhang MC and Liu H: The antineoplastic mechanism of the extract B of Polygonatum odoratum. Zhong Guo Mian Yi Xue Za Zhi. 4:253–254. 2003.(In Chinese).
29	Zhang H, Chen L, Kou JP, Zhu DN, Qi J and Yu BY: Steroidal sapogenins and glycosides from the fibrous roots of Polygonatum odoratum with inhibitory effect on tissue factor (TF) procoagulant activity. Steroids. 89:12014. View Article : Google Scholar : PubMed/NCBI
30	Deng Y, He K, Ye X, Chen X, Huang J, Li X, Yuan L, Jin Y, Jin Q and Li P: Saponin rich fractions from Polygonatum odoratum (Mill.) Druce with more potential hypoglycemic effects. J Ethnopharmacol. 141:228–233. 2012. View Article : Google Scholar : PubMed/NCBI
31	Park S, Hong SM, Ahn IS, Kim YJ and Lee JB: Huang-Lian-Jie-Du-Tang supplemented with Schisandra chinensis Baill and Polygonatum odoratum Druce improved glucose tolerance by potentiating insulinotropic actions in islets in 90% pancreatectomized diabetic rats. Biosci Biotechnol Biochem. 73:2384–2392. 2009. View Article : Google Scholar : PubMed/NCBI
32	Park S, Hong SM, Ahn IS, Kim YJ and Lee JB: Huang-Lian-Jie-Du-Tang supplemented with Schisandra chinensis Baill. and Polygonatum odoratum Druce improved glucose tolerance by potentiating insulinotropic actions in islets in 90% pancreatectomized diabetic rats. Biosci Biotechnol Biochem. 73:2384–2392. 2009.
33	Yang Y, Xu HL, Zhang ZT, Liu JJ, Li WW, Ming H and Bao JK: Characterization, molecular cloning, and in silico analysis of a novel mannose-binding lectin from Polygonatum odoratum (Mill.) with anti-HSV-II and apoptosis-inducing activities. Phytomedicine. 18:748–755. 2011. View Article : Google Scholar : PubMed/NCBI
34	Ouyang L, Chen Y, Wang XY, Lu RF, Zhang SY, Tian M, Xie T, Liu B and He G: Polygonatum odoratum lectin induces apoptosis and autophagy via targeting EGFR-mediated Ras-Raf-MEK-ERK pathway in human MCF-7 breast cancer cells. Phytomedicine. 21:1658–1665. 2014. View Article : Google Scholar : PubMed/NCBI
35	Rafi MM and Vastano BC: Identification of a structure specific Bcl-2 phosphorylating homoisoflavone molecule from Vietnamese coriander (Polygonatum odoratume) that induces apoptosis and G2/M cell cycle arrest in breast cancer cell lines. Food Chem. 104:332–340. 2007. View Article : Google Scholar
36	Yang H, Huang WR and Yu L: Clinical application and research process of novel antitumor drug. J New Med. 19:480–485. 2010.
37	Vaux DL: Apoptosis timeline. Cell Death Differ. 9:349–354. 2002. View Article : Google Scholar : PubMed/NCBI
38	Edinger AL and Thompson CB: Death by design: Apoptosis, necrosis and autophagy. Curr Opin Cell Biol. 16:663–669. 2004. View Article : Google Scholar : PubMed/NCBI
39	Vaux DL, Cory S and Adams JM: Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature. 335:440–442. 1988. View Article : Google Scholar : PubMed/NCBI
40	Wang T, Liu CZ, Liu YZ, Yu JC and Han JX: Research progress of Bcl-2/Bax gene regulated mechanism for organism cell apoptosis. Zhong Guo Lao Nian Xue Za Zhi. 16:1658–1660. 2008.(In Chinese).
41	Li M and Lin J: The apoptotic pathways and their mechanisms. Guo Ji Fu Chan Ke Xue Za Zhi. 2:103–107. 2014.(In Chinese).
42	Xu RR and Li YD: Research progress of Bcl-2 families interact with mitochondrial apoptosis pathway. Zhong Guo Lao Nian Xue Za Zhi. 12:2977–2979. 2013.(In Chinese).
43	Oltvai ZN, Milliman CL and Korsmeyer SJ: Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell. 74:609–619. 1993. View Article : Google Scholar : PubMed/NCBI
44	Alsabeh R, Wilson CS, Ahn CW, Vasef MA and Battifora H: Expression of Bcl-2 by breast cancer: A possible diagnostic application. Mod Pathol. 9:439–444. 1996.PubMed/NCBI
45	Garner DL, Thomas CA, Joerg HW, DeJarnette JM and Marshall CE: Fluorometric assessments of mitochondrial function and viability in cryopreserved bovine spermaotozoa. Biol Reprod. 57:1401–1406. 1997. View Article : Google Scholar : PubMed/NCBI
46	Castedo M, Ferri K, Roumier T, Métivier D, Zamzami N and Kroemer G: Quantitation of mitochondrial alterations associated with apoptosis. J Immunol Methods. 265:39–47. 2002. View Article : Google Scholar : PubMed/NCBI
47	Baxa DM, Luo X and Yoshimura FK: Genistein induces apoptosis in T lymphoma cells via mitochondrial damage. Nutr Cancer. 51:93–101. 2005. View Article : Google Scholar : PubMed/NCBI
48	Tan YC, Chen ZJ, Lu SM and Gao X: Detection of mitochondrial membrane potential changes in spermatozoa by fluorescent dyes JC-1. Shan Dong Da Xue Xue Bao. 5:447–450. 2006.(In Chinese).
49	Xia XY, Wu YM, Hou BS, Yang B, Pan LJ, Shi YC, Jin BF, Shao Y, Cui YX and Huang YF: Evaluation of sperm mitochondrial membrane potential by JC-1 fluorescent staining and flow cytometry. Zhonghua Nan Ke Xue. 14:135–138. 2008.(In Chinese). PubMed/NCBI
50	Wang L, Yao SM and Wang Q: The mechanism of mitochondrial impairment induced by cadmium. Huan Jing Yu Zhi Ye Yi Xue. 23:73–75. 2006.(In Chinese).